Drug Discovery Today: Technologies最新文献_第4页

Viral safety for biotherapeutics and biosimilar 生物治疗药物和生物仿制药的病毒安全性

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2020.08.001

Horst Ruppach

引用次数: 0

A drug discovery toolbox for Nuclear Magnetic Resonance (NMR) characterization of ligands and their targets 一个用于核磁共振(NMR)表征配体及其靶标的药物发现工具箱

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2020.11.008

Regan M. LeBlanc, Michael F. Mesleh

引用次数: 4

Synthetic carbohydrate-based cell wall components from Staphylococcus aureus 从金黄色葡萄球菌合成碳水化合物为基础的细胞壁成分

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.01.003

Francesca Berni, Jacopo Enotarpi, Thijs Voskuilen, Sizhe Li, Gijs A. van der Marel, Jeroen D.C. Codée

引用次数: 2

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.06.001

Zoltán Urbányi

引用次数: 0

Precise protein conjugation technology for the construction of homogenous glycovaccines 构建均质糖疫苗的精确蛋白偶联技术

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2020.11.007

Annabel Kitowski , Francisco Corzana , Gonçalo J.L. Bernardes

{"title":"Precise protein conjugation technology for the construction of homogenous glycovaccines","authors":"Annabel Kitowski , Francisco Corzana , Gonçalo J.L. Bernardes","doi":"10.1016/j.ddtec.2020.11.007","DOIUrl":"10.1016/j.ddtec.2020.11.007","url":null,"abstract":"<div>The introduction of vaccines for the treatment and prevention of bacterial or viral diseases in the early 19th century marked a crucial turning point in medical history. Since then, extensive immunization campaigns have eradicated smallpox and drastically reduced the number of diphtheria, tetanus, pertussis and measles cases worldwide. Although a broad selection of vaccines is available, there remains a need to develop additional vaccine candidates against a range of dangerous infectious diseases, preferably based on precise syntheses that lead to homogenous formulations. Different strategies for the construction of this type of vaccine candidates are being pursued. Glycoconjugate vaccines are successful in the fight against bacterial and viral infectious diseases. However, their exact mechanism of action remains largely unknown and the large-scale production of chemically defined constructs is challenging. In particular, the conjugation of the carbohydrate antigen to the protein carrier has proved to be crucial for the properties of these vaccines. This review highlights some of the latest findings and developments in the construction of glycoconjugate vaccines by means of site-specific chemical reactions.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.11.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39717544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-β-(1→6)-N-acetyl-d-glucosamine exopolysaccharide 具有广泛保护作用的半合成糖缀合物疫苗，可抵抗产生聚β-(1→6)- n -乙酰-d-氨基葡萄糖外多糖的病原体

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2020.09.002

Marina L. Gening , Gerald B. Pier , Nikolay E. Nifantiev

{"title":"Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-β-(1→6)-N-acetyl-d-glucosamine exopolysaccharide","authors":"Marina L. Gening , Gerald B. Pier , Nikolay E. Nifantiev","doi":"10.1016/j.ddtec.2020.09.002","DOIUrl":"10.1016/j.ddtec.2020.09.002","url":null,"abstract":"<div>Poly-β-(1→6)-N-acetylglucosamine (PNAG) was first discovered as a major component of biofilms formed by Staphylococcus aureus and some other staphylococci but later this exopolysaccharide was also found to be produced by pathogens of various nature. This common antigen is considered as a promising target for construction of a broadly protective vaccine. Extensive studies of PNAG, its de-N-acetylated derivative (dPNAG, containing around 15% of residual N-acetates) and their conjugates with Tetanus Toxoid (TT) revealed the crucial role of de-N-acetylated glucosamine units for the induction of protective immunity. Conjugates of synthetic penta- (5GlcNH2) and nona-β-(1→6)-d-glucosamines (9GlcNH2) were tested in vitro and in different animal models and proved to be effective in passive and active protection against different microbial pathogens. Presently conjugate 5GlcNH2-TT is being produced under GMP conditions and undergoes safety and effectiveness evaluation in humans and economically important animals. Current review summarizes all stages of this long-termed study.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2020.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39108119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Erratum regarding missing Declaration of Competing Interest statements in previously published articles 关于先前发表的文章中缺少竞争利益声明的勘误表

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.01.001

引用次数: 0

Escape from planarity in fragment-based drug discovery: A physicochemical and 3D property analysis of synthetic 3D fragment libraries 在基于片段的药物发现中逃避平面性:合成三维片段文库的物理化学和三维性质分析

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.05.001

David J. Hamilton , Tom Dekker , Hanna F. Klein , Guido V. Janssen , Maikel Wijtmans , Peter O’Brien , Iwan J.P. de Esch

{"title":"Escape from planarity in fragment-based drug discovery: A physicochemical and 3D property analysis of synthetic 3D fragment libraries","authors":"David J. Hamilton , Tom Dekker , Hanna F. Klein , Guido V. Janssen , Maikel Wijtmans , Peter O’Brien , Iwan J.P. de Esch","doi":"10.1016/j.ddtec.2021.05.001","DOIUrl":"10.1016/j.ddtec.2021.05.001","url":null,"abstract":"<div>Fragment-based drug discovery (FBDD) has grown into a well-established approach in the pursuit of new therapeutics. Key to the success of FBDD is the low molecular complexity of the initial hits and this has resulted in fragment libraries that mainly contain compounds with a two-dimensional (2D) shape. In an effort to increase the chemical diversity and explore the impact of increased molecular complexity on the hit rate of fragment library screening, several academic and industrial groups have designed and synthesised novel fragments with a three-dimensional (3D) shape. This review provides an overview of 25 synthetic 3D fragment libraries from the recent literature. We calculate and compare physicochemical properties and descriptors that are typically used to measure molecular three-dimensionality such as fraction sp3 (Fsp3), plane of best fit (PBF) scores and principal moment of inertia (PMI) plots. Although the libraries vary widely in structure and properties, some key common features can be identified which may have utility in designing the next generation of 3D fragment libraries.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39717545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Microbial technologies for biotherapeutics production: Key tools for advanced biopharmaceutical process development and control 生物治疗药物生产的微生物技术:先进生物制药工艺开发和控制的关键工具

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.04.001

Denes Zalai , Julian Kopp , Bence Kozma , Michael Küchler , Christoph Herwig , Julian Kager

{"title":"Microbial technologies for biotherapeutics production: Key tools for advanced biopharmaceutical process development and control","authors":"Denes Zalai , Julian Kopp , Bence Kozma , Michael Küchler , Christoph Herwig , Julian Kager","doi":"10.1016/j.ddtec.2021.04.001","DOIUrl":"10.1016/j.ddtec.2021.04.001","url":null,"abstract":"<div>Current trends in the biopharmaceutical market such as the diversification of therapies as well as the increasing time-to-market pressure will trigger the rethinking of bioprocess development and production approaches. Thereby, the importance of development time and manufacturing costs will increase, especially for microbial production.In the present review, we investigate three technological approaches which, to our opinion, will play a key role in the future of biopharmaceutical production. The first cornerstone of process development is the generation and effective utilization of platform knowledge. Building processes on well understood microbial and technological platforms allows to accelerate early-stage bioprocess development and to better condense this knowledge into multi-purpose technologies and applicable mathematical models. Second, the application of verified scale down systems and in silico models for process design and characterization will reduce the required number of large scale batches before dossier submission. Third, the broader availability of mathematical process models and the improvement of process analytical technologies will increase the applicability and acceptance of advanced control and process automation in the manufacturing scale. This will reduce process failure rates and subsequently cost of goods. Along these three aspects we give an overview of recently developed key tools and their potential integration into bioprocess development strategies.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39717546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Gold nanoparticle-based platforms for vaccine development 基于金纳米粒子的疫苗开发平台

Drug Discovery Today: Technologies Pub Date : 2020-12-01 DOI: 10.1016/j.ddtec.2021.02.001

Ruth Mateu Ferrando , Luigi Lay , Laura Polito

引用次数: 31